Document Type : Original Article
Abstract
Keywords
Mobile Number:201096834342
ABSTRACT
Introduction: Interstitial lung disease (ILD) and thyroid illnesses are common pediatric diseases. However, to date their link is not well-studied.
Aim: To study thyroid hormone levels in children with interstitial lung disease (chILD) and to assess the relationship between thyroid hormone abnormalities and disease severity.
Method: This is a case-control pilot study that was conducted on 25 patients with chILD and 25 healthy controls recruited from Pulmonology clinic, Children’s Hospital Ain Shams University during the period from October 2023 to April 2024. History taking and clinical examination, FEV1%, and FVC %, oxygen saturation, chest computed tomography and FT3, FT4 and TSH were done for the patients and control.
Method of Selection: consecutive sample method.
Results: Mean ±SD of weight SDS (-0.68±3.26) and height SDS (-1.6±2.2) were statistically significantly lower in chILD patients compared to controls (1.3±0.69 & 1.17 ±0.81 respectively) (p < 0.0001). Symptoms suggestive of thyroid hyperfunction were higher in patients than in controls as weather intolerance (48% vs. 0%) (p < 0.0001) and weight loss (32% vs. 0%) (p = 0.002). Free T3 levels were normal yet statistically significantly higher in patients (3.379 ± 0.6900 pg/L) compared to controls (2.099 ± 0.4552 pmol/L) (p < 0.0001). TSH levels were normal yet not statistically significantly lower in patients (1.880±0.8447) than in controls (2.058 ± 0.4821). Mean ±SD of FEV1 % was 41.00 ± 15.51, FVC % was 46.27 ± 14.92, and MEFF % was 26.30 ± 17.44. Oxygen saturation was 93.00 ± 3.041% at rest and 88.48 ± 3.938% during exercise. No correlation was found between thyroid hormone levels and spirometry values, clinical severity, or oxygen saturation.
Conclusion: Children with chILD may exhibit symptoms of thyroid gland dysfunction in the form of (heat intolerance, cold intolerance, weight loss and weight gain) and have normal thyroid hormone levels. Further research is needed to explore the relation between thyroid hormones and chILD.
Keywords: Interstitial Lung Disease (ILD), Thyroid Dysfunction, Pulmonary Function Tests
Introduction
Background: Children's interstitial lung disease (chILD) is a heterogeneous group of rare and diffuse lung conditions that significantly impact pediatric health. ILD affects the interstitium, airways, alveolar spaces, vascular beds, lymphatic channels, and pleural spaces, and are characterized by considerable morbidity and mortality (Ferraro et al., 2020; Ionescu et al., 2022). The increasing incidence of chILD in recent years likely resulted from better diagnostic tools and the greater awareness of rare pediatric diseases among healthcare providers (Nayir et al., 2023). Thyroid hormones (TH), essential endocrine regulators of metabolic and developmental processes, have been implicated in a wide range of physiological and pathological processes, including those affecting the pulmonary system. Assessing TH in lung diseases has been of riding interest over the last few years (Gloriane et al.,2022).
Despite accumulating evidence in adult populations, the impacts of thyroid function on pediatric lung diseases, particularly chILD, have not been well investigated. The existing literature focuses mainly on adult conditions and shows that there is a scarcity of information on how these dynamics play out in children. Few studies have pointed out possible areas of interest but have not explored the specific applications in children (Oldham et al., 2015). This study aims at filling this gap by exploring the correlation between thyroid hormone levels and the severity of ILD in pediatric populations. By doing so, it could offer basic foundational knowledge that may result in new therapeutic strategies tailored to the specific needs of children with chILD (Breitzig et al., 2018).
Aim of the Study: To study thyroid hormone levels in children with interstitial lung disease (chILD) and to assess the relationship between thyroid hormone abnormalities and disease severity.
Methods:
Ethical considerations:
1.The study was conducted after approval of the protocol by The Research Committee local and The Studies Committee well as the Research Ethics Committee under number: FMASU MS 515/2023
2.An informed written consent was obtained from all study population and it will contain the following: The aim and methods of the study in simple way.
3.The patients have the right to refuse participation or withdraw without affecting medical care at any time without any penalty.
4.Confidentiality of all data and results of all study population was preserved.
5.declaire: there is no conflict of interest or funding for the study and publication.
Sample Size calculation:
Considering that chILD is a rare disease, all available patient fulfilling inclusion criteria during study duration were included in the study.
No formal sample size calculation was performed.
Inclusion criteria: Children diagnosed with interstitial lung diseases.
Age group: 2- 18 years
Exclusion criteria included patients younger than 2 years, those with other lung diseases, suspected syndromes, proven thyroid disorders, or those taking drugs that affect thyroid function. The study also included 25 age and sex matched healthy children serving as controls.
Study Setting and Design
The study was conducted at the Pulmonology clinic, Children’s Hospital Ain Shams University. It employed a cross-sectional design over a period of six months from October 2023 to April 2024.
Type of the Study: case - control pilot Study
Study Population
The study population included 25 children aged 2-18 years diagnosed with interstitial lung diseases, with at least three of the following criteria: respiratory symptoms, clinical signs of respiratory insufficiency, hypoxemia or low pulsed oxygen saturation, and diffuse parenchymal lung disease on chest radiography or thoracic CT scan (Nathan et al., 2023).
Study Tools and Data Collection:
All studied patients were subjected to:
1.Full history was collected from patients and their caregivers, including socio-demographic data (age, gender, socioeconomic status, consanguinity of parents), history of symptoms related to interstitial lung diseases (dyspnea, shortness of breath, exercise intolerance, chronic cough), history suggestive of thyroid disorders (weight changes, temperature intolerance, exophthalmos), family history of thyroid disorders or interstitial lung diseases, and history of drug intake.
2.Clinical examination included vital data measurements (respiratory rate, heart rate, and blood pressure), anthropometric measurements (height and its standard deviation score (SDS), weight and its SDS, systemic examination with stress on respiratory examination and thyroid dysfunction (goiter and exophthalmos) and other systemic examination (neurological, cardiac, abdominal), and signs of hypo or hyperthyroidism (goiter, exophthalmos). The chILD severity score was recorded for each subject on presentation as follows:
Grade 0: Asymptomatic
Grade 1: Symptomatic: normal oxygen saturation under all conditions
Grade 2: Symptomatic: normal resting room air saturation, but hypoxemia <90% with exercise or sleep Grade 3: Symptomatic, hypoxemia <90% at rest
Grade 4: Symptomatic, hypoxemia at rest and pulmonary hypertension (Schapiro AH et al., 2022).
3. Spirometry pulmonary function tests (forced expiratory volume in the first second (FEV1%), forced vital capacity (FVC%), maximum expiratory flow (MEFF%)) was done for cooperative children with age above 7 years and obtained values were expressed as percentage of expected for age and sex. Laboratory investigations by collecting a 5 ml blood sample from each patient to measure free T4, free T3, and TSH levelsusing the available ELISA kits.
4. Computed tomography of the chest for all patients.
Statistical Methods
Results :
Table (1): Demographic and anthropometric of the studied groups
Parameters |
Cases group (N=25) |
Control group (N=25) |
P |
|||
|
N |
% |
N |
% |
|
|
Age(years) |
Mean |
9.683 |
10.50 |
0.4503 |
||
|
SD |
4.122 |
3.434 |
|||
Sex |
Male |
12 |
48 |
14 |
56 |
0.57 |
Female |
13 |
52 |
11 |
44 |
||
Tanner staging |
Stage 1 |
19 |
76 |
17 |
68 |
0.5287 |
Stage 2 |
0 |
0 |
0 |
0 |
||
Stage 3 |
6 |
24 |
8 |
32 |
||
Weight SDs |
Mean |
-0.6864 |
1.307 |
0.0044 |
||
SD |
3.263 |
0.6976 |
||||
Height SDs |
Mean |
-1.618 |
1.169 |
<0.0001 |
||
SD |
2.215 |
0.8114 |
This table shows that weight and height were significant lower in cases than control patients.
Table (2): clinical and laboratory finding of thyroid dysfunction of the 2 groups
Parameters |
Cases group (N=25) |
Control group (N=25) |
P |
|||
|
N |
% |
N |
% |
|
|
Symptoms of hyperthyroidism |
||||||
Weight loss |
Negative |
17 |
68 |
25 |
100 |
0.0020 |
Positive |
8 |
32 |
0 |
0 |
||
Exophthalmos |
Negative |
25 |
100 |
25 |
100 |
- |
Positive |
0 |
0 |
0 |
0 |
||
Heat intolerance |
Negative |
21 |
84 |
25 |
100 |
0.0371 |
Positive |
4 |
16 |
0 |
0 |
||
Symptoms of hypothyroidism |
||||||
Weight gain |
Negative |
22 |
88 |
25 |
100 |
0.0740 |
Positive |
3 |
12 |
0 |
0 |
||
Cold intolerance |
Negative |
17 |
68 |
25 |
100 |
0.0020 |
Positive |
8 |
32 |
0 |
0 |
||
Thyroid profile |
||||||
FT3 (pg./mL) |
Mean |
3.379 |
2.099 |
<0.0001 |
||
SD |
0.69 |
0.4552 |
||||
Min-Max |
2.22-4.8 |
1.24-3.15 |
||||
FT4 (ng/dL) |
Mean |
1.421 |
1.556 |
0.2495 |
||
SD |
0.4555 |
0.3561 |
||||
Min-Max |
1-3.4 |
1-2.6 |
||||
TSH (mIU/L) |
Mean |
1.880 |
2.058 |
0.3647 |
||
SD |
0.8447 |
0.4821 |
||||
Min-Max |
0.03-3.88 |
1.48-2.99 |
This table shows that:
Table (3): Symptoms and Signs of Interstitial Lung Disease among Cases
Symptoms of ILD |
chILD cases (N=25) |
||
N |
% |
||
Dyspnea |
Positive |
24 |
96 |
Negative |
1 |
4 |
|
Exercise intolerance |
Positive |
23 |
92 |
Negative |
2 |
8 |
|
Chronic cough |
Positive |
16 |
64 |
Negative |
9 |
36 |
|
RD staging |
1 |
4 |
16 |
|
2 |
15 |
60 |
|
3 |
5 |
20 |
|
4 |
1 |
4 |
ILD staging |
0 |
1 |
4 |
|
1 |
12 |
48 |
|
2 |
3 |
12 |
|
3 |
3 |
12 |
|
4 |
6 |
24 |
ILD: Interstitial lung disease.
This table shows that:
Table (4): Vital Signs and Spirometry Findings among Cases
Vital signs and spirometry findings |
chILD cases (N=25) |
|
SPO2 at rest (%) |
Mean |
93.00 |
SD |
3.041 |
|
Min-Max |
88-99 |
|
SPO2 at exercise (%) |
Mean ± SD |
88.48 |
SD |
3.938 |
|
Min-Max |
88-93 |
|
FEV1 (%) |
Mean |
41.00 |
SD |
15.51 |
|
Min-Max |
16-83.2 |
|
FVC (%) |
Mean |
46.27 |
SD |
14.92 |
|
Min-Max |
16-90.2 |
|
MMEF (%) |
Mean |
26.30 |
SD |
17.44 |
|
Min-Max |
8-82 |
FEV1: Forced expiratory volume in 1 second, FVC: Forced vital capacity, MMEF: Maximum mid-expiratory flow, SPO2: Oxygen saturation.
This table shows that:
Table (6): Correlation of Thyroid Function Tests with Other Parameters
Parameters |
T3 (pg./mL) |
T4 (ng/dL) |
TSH (mIU/L) |
|||
|
r |
p |
r |
p |
r |
p |
RD staging |
-0.22 |
0.29 |
-0.037 |
0.86 |
0.213 |
0.307 |
ILD staging |
-0.14 |
0.504 |
-0.289 |
0.161 |
-0.066 |
0.754 |
Radiological changes |
-0.05 |
0.811 |
-0.051 |
0.809 |
-0.226 |
0.279 |
SPO2 at rest (%) |
-0.013 |
0.952 |
0.267 |
0.196 |
-0.077 |
0.714 |
SPO2 at exercise (%) |
-0.104 |
0.619 |
0.245 |
0.237 |
-0.351 |
0.086 |
FEV1 (%) |
-0.236 |
0.397 |
-0.022 |
0.938 |
-0.286 |
0.302 |
FVC (%) |
0.11 |
0.696 |
-0.04 |
0.887 |
-0.043 |
0.889 |
MMEF (%) |
-0.126 |
0.654 |
-0.151 |
0.592 |
-0.476 |
0.073 |
FEV1: Forced expiratory volume in 1 second, FVC: Forced vital capacity, ILD: Interstitial lung disease, MMEF: Maximum mid-expiratory flow, RD: Respiratory distress, SPO2: Oxygen saturation. FT3: free triiodothyronine, FT4: free thyroxine, TSH: Thyroid stimulating hormone, r: correlation coefficient, p: p-value >0.05: Non-significant; p-value <0.05: Significant; p-value< 0.01: Highly significant
This table shows that:
Discussion
the impacts of thyroid function on pediatric lung diseases, particularly chILD, have not been well investigated.
Our aim of this study was to assess TH abnormalities in children with interstitial lung disease (chILD) and their relationship to the severity of the disease.
Our result showed that the anthropometric measurements (weight and height) were significantly lower in children with chILD compared to controls, aligning with the chronic nature of chILD that often affects growth and development. Symptoms such as weather intolerance and weight loss were significantly more prevalent among children with chILD. Free T3 levels were significantly higher in children with chILD compared to controls, indicating a potential disruption in thyroid function associated with the disease. Although TSH levels were lower in the chILD group, this difference was not statistically significant. These finding suggest a possible link between thyroid dysfunction and clinical symptoms in this disease. Pulmonary function tests indicated significantly reduced FEV1, FVC, and MMEF values in children with chILD, reflecting the impact of the disease on lung function. No significant correlations were found between thyroid hormone levels and spirometry values, clinical severity, or oxygen saturation percentages.
The findings of this study align with previous research that indicates a link between thyroid dysfunction and pulmonary diseases. Previous research has shown the impact of thyroid hormones on metabolic rate, energy expenditure, and mitochondrial function, all of which are linked to lung function (Nathan et al ,2023). The imbalance of thyroid hormones can lead to metabolic disorders affecting systemic metabolism and lung function, which emphasizes the interconnectedness of the endocrine and respiratory system. Furthermore, Nathan et al. (2023) discussed the approach to children with interstitial lung disease and emphasized that patients should undergo extensive diagnostic workup, including endocrine assessments. Their finding suggests that understanding the patient’s endocrine status can help develop better management strategies and enhance clinical results (Nathan et al., 2023). Garg et al. (2023) recruited 30 newly diagnosed hypothyroid adult patients and 30 healthy controls in India to assess pulmonary function in newly diagnosed hypothyroid patients. 17% of the hypothyroid patients were normal, whereas 33% had mild restrictive lung impairment and the rest 50% had moderate to severe restrictive impairment on spirometry where the ventilatory functions were diminished and improved after levothyroxine therapy for 6 months but could not reach the normal healthy values. This aligns with the current study’s recommendations for regular thyroid function screening in children with ILD.
Ali ER (2016) explored the functional lung impairment in patients with thyroid disorders and revealed significant respiratory complications associated with both hypothyroidism and hyperthyroidism. Ali's study showed that hypothyroidism was linked to decreased respiratory drive and various respiratory complications, while hyperthyroidism could increase respiratory drive and also caused dyspnea on exertion. These findings highlighted the important need for managing thyroid function in patients with lung diseases to prevent further respiratory impairment. The focus of this study, was the relationship between thyroid hormone abnormalities and disease severity in children with ILD, aligning with Ali's findings, which emphasizes the importance of early detection and the comprehensive management of thyroid hormonal imbalances, especially in patients with ILD. In addition, Oldham et al. (2015) found a high prevalence of hypothyroidism in patients with idiopathic pulmonary fibrosis (IPF) and suggested that hypothyroidism might serve as a mortality indicator. This aligned with the altered TH levels observed in this study, which may reflect an altered metabolic state associated with chILD. However, the absence of significant correlations between thyroid hormone levels and clinical parameters suggests that the relationship between thyroid function and lung disease severity is complex and depends on multiple factors.
The clinical implications of these findings are significant. The results of the study indicate the necessity of periodic thyroid function assessment in children with pulmonary diseases as the abnormalities in thyroid function tests could be early signs of the progression of the disease and detecting them could guide its treatment. Given the complex interplay between TH and lung health, a multidisciplinary approach involving endocrinologists and pulmonologists may be necessary to optimize patient outcomes. Therefore, the results of the current study and its findings are consistent with previous research that emphasized the importance of thyroid hormones in lung development and pathology. The observed increase in T3 levels in children with ILD supports the general trend of TH disruption in regulating pulmonary function and disease progression. These findings highlight the need for integrated clinical strategies that address both endocrine and respiratory health to improve outcomes for pediatric patients with lung diseases.
Strengths and Limitations
The study utilized a well-defined cohort of children with chILD, thus allowing for focused assessment of thyroid function in this particular population. Robust data collection methods, including comprehensive clinical assessments and standardized thyroid function tests were used to ensure the accuracy of the data.
The number of cases used was relatively small, which may reduce the generalizability of the results so the second question of the study could not be answered. Further research with a higher patient population is required to confirm this study’s findings. Additionally, the cross-sectional design of the study prevents the establishment of casual relationships between thyroid function and chILD severity. Future research has to involve the performance of longitudinal analysis to establish the causal link between dysfunction and diseases progression. Moreover, some limitations of the study include the lack of information on the patients’ nutritional status, medication use, or other co-existing conditions that may affect thyroid function and lung disease severity, which could have impacted the results.
Conclusion
The findings of this study suggest that there is a complex relationship between thyroid function and interstitial lung disease in children. The observed increase in free T3 levels in children with chILD suggests that there may be a potential link that warrants further investigations. Routine thyroid function tests should be done in this population to assist in early detection and management of thyroid abnormalities. Understanding these connections might lead to new therapeutic options, which could improve clinical outcomes for children with chILD.
Recommendation
Based on the findings of this study, the study underlines the importance of considering thyroid health in managing pediatric interstitial lung diseases. So, the following recommendations can be proposed. Firstly, implementing routine thyroid function tests for children diagnosed with chILD is recommended to assist in early detection of thyroid abnormalities. Secondly, more studies should be done to analyze the causal relationships between the two conditions in children through the use of longitudinal research. Thirdly, it is recommended to investigate the molecular mechanisms linking thyroid hormones and lung pathology to identify potential therapeutic targets. Lastly, developing comprehensive care protocols that includes both the pulmonary and endocrine aspects of chILD can enhance patient outcomes and quality of life.
References
Ali ER. (2016): Assessment of functional lung impairment in patients with thyroid disorders. Egyptian journal of Bronchology,10: 337–347.
Breitzig MT, Alleyn MD, Lockey RF and Kolliputi N. (2018): Thyroid hormone: a resurgent treatment for an emergent concern. American journal of physiology. Lung cellular and molecular physiology, 315(6): L945–L950.
Ferraro VA, Zanconato S, Zamunaro A and Carraro S. (2020): Children's Interstitial and Diffuse Lung Diseases (ChILD) in 2020. Children (Basel), 7(12):280.
Gloriane C, Luna H, Severino Imasa M, Juat NS., Hernandez KV, May Sayo T, et al. (2022). Expression landscapes in non-small cell lung cancer shaped by the thyroid transcription factor 1. Lung cancer, 176:121-131.
Garg N, Kumar V, Gupta KB and Garg S (2023): Evaluation of Ventilatory Functions in Hypothyroid Patients. The Egyptian Journal of chest diseases and tuberculosis, 72(1): 65-69.
Ionescu MD, Popescu, NA, Stănescu D, Enculescu A, Bălgrădean M, Căpitănescu GM, et al. (2022): The Challenging Diagnosis of Interstitial Lung Disease in Children-One Case Report and Literature Review. Journal of clinical medicine, 11(22): 6736.
Mendoza A and Hollenberg AN. (2017): New insights into thyroid hormone action. Pharmacology & therapeutics, 173:135-145.
Nathan N, Griese M, Michel K, Carlens J, Gilbert C, Emiralioglu N, et al (2023): Diagnostic workup of childhood interstitial lung disease. European Respiratory Review, 32(167): 220188.
Nayir Buyuksahin H, Kiper N (2023): Childhood interstitial lung disease. Pediatric allergy, immunology and pulmonology, 36(1): 5-15.
Oldham JM, Kumar D, Lee C, Patel SB, Takahashi-Manns S, Demchuk C, et al (2015): Thyroid disease is prevalent and predicts survival in patients with idiopathic pulmonary fibrosis. Chest, 148(3):692-700.
Papaioannou O, Karampitsakos T, Barbayianni I, Chrysikos S, Xylourgidis N and Tzilas V (2018): Bouros D, Aidinis V and Tzouvelekis A. Metabolic Disorders in Chronic Lung Diseases. Frontiers in medicine, 4:246. ff.
SatoY., Tanino Y, Nikaido T, Togawa R, Kawamata T, Wang X, Shibata Y. et al. (2020): Clinical significance of thyroid hormone and antibodies in patients with idiopathic interstitial pneumonia. Journal of thoracic disease, 12(3): 522-537.
Vrigkou E, Vassilatou E, Dima E, Langleben D, Kotanidou A and Tzanela M. (2022): The Role of Thyroid Disorders, Obesity, Diabetes Mellitus and Estrogen Exposure as Potential Modifiers for Pulmonary Hypertension. Journal of clinical medicine, 11(4):921.
Wong AW, Ryerson CJ and Guler SA (2020): Progression of fibrosing interstitial lung disease. Respiratory research, 21(1):32.
Yi K, Tian M and Li X. (2024): The Influence of Autoimmune Thyroid Diseases on Viral Pneumonia Development, Including COVID-19: A Two-Sample Mendelian Randomization Study. Pathogens, 13:101.
Zhang L, Wang W, Zhu B and Wang X. (2017): Epithelial mitochondrial dysfunction in lung disease. Mitochondrial DNA, 1038(1):201-21.